Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.

Wirnsberger, Gerald; Monteil, Vanessa; Eaton, Brett; Postnikova, Elena; Murphy, Michael; Braunsfeld, Benedict; Crozier, Ian; Kricek, Franz; Niederhöfer, Janine; Schwarzböck, Alice; Breid, Helene; Jimenez, Anna Sanchez; Bugajska-Schretter, Agnes; Dohnal, Alexander; Ruf, Christine; Gugenberger, Romana; Hagelkruys, Astrid; Montserrat, Nuria; Holbrook, Michael R; Oostenbrink, Chris; Shoemaker, Robert H; Mirazimi, Ali; Penninger, Josef M

Wirnsberger, Gerald; Monteil, Vanessa; Eaton, Brett; Postnikova, Elena; Murphy, Michael; Braunsfeld, Benedict; Crozier, Ian; Kricek, Franz; Niederhöfer, Janine; Schwarzböck, Alice; Breid, Helene; Jimenez, Anna Sanchez; Bugajska-Schretter, Agnes; Dohnal, Alexander; Ruf, Christine; Gugenberger, Romana; Hagelkruys, Astrid; Montserrat, Nuria; Holbrook, Michael R; Oostenbrink, Chris; Shoemaker, Robert H; Mirazimi, Ali; Penninger, Josef M.

Afiliação

Wirnsberger G; Apeiron Biologics, Vienna, Austria.
Monteil V; Karolinska Institutet and Karolinska University Hospital, Unit of Clinical Microbiology, SE-17182, Stockholm, Sweden.
Eaton B; NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Postnikova E; NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Murphy M; NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Braunsfeld B; Institute for Molecular Modeling and Simulation, University of Natural Resources and Life Sciences (BOKU), Austria.
Crozier I; NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Kricek F; NBS-C BioScience & Consulting GmbH, Vienna, Austria.
Niederhöfer J; Apeiron Biologics, Vienna, Austria.
Schwarzböck A; Apeiron Biologics, Vienna, Austria.
Breid H; Apeiron Biologics, Vienna, Austria.
Jimenez AS; Apeiron Biologics, Vienna, Austria.
Bugajska-Schretter A; Apeiron Biologics, Vienna, Austria.
Dohnal A; Apeiron Biologics, Vienna, Austria.
Ruf C; NBS-C BioScience & Consulting GmbH, Vienna, Austria.
Gugenberger R; Apeiron Biologics, Vienna, Austria.
Hagelkruys A; Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.
Montserrat N; Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Holbrook MR; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
Oostenbrink C; NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Shoemaker RH; Institute for Molecular Modeling and Simulation, University of Natural Resources and Life Sciences (BOKU), Austria.
Mirazimi A; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Penninger JM; Karolinska Institutet and Karolinska University Hospital, Unit of Clinical Microbiology, SE-17182, Stockholm, Sweden.

bioRxiv ; 2021 Sep 10.

Article em En | MEDLINE | ID: mdl-34545368

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: BioRxiv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Áustria